SCM
RXRX icon

Sterling Capital Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Sterling Capital Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35K Buy
9,533
+6,557
+220% +$21.8K ﹤0.01% 1675
2026
Q1 		$9.14K Buy
2,976
+540
+22% +$2.09K ﹤0.01% 2415
2025
Q4 		$9.96K Buy
2,436
+1,547
+174% +$7.66K ﹤0.01% 2602
2025
Q3 		$4.34K Buy
889
+68
+8% +$357 ﹤0.01% 2800
2025
Q2 		$4.15K Buy
821
+556
+210% +$2.73K ﹤0.01% 2611
2025
Q1 		$1.4K Buy
265
+15
+6% +$109 ﹤0.01% 2703
2024
Q4 		$1.69K Buy
250
+12
+5% +$81 ﹤0.01% 2824
2024
Q3 		$1.57K Buy
+238
New +$1.71K ﹤0.01% 2310

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Sterling Capital Management's RXRX Position: Q2 2026 in Review

Sterling Capital Management increased its Recursion Pharmaceuticals (RXRX) stake by 220% in Q2 2026, buying an estimated $21.8K and bringing the position to 9,533 shares worth $35K. The position accounts for ﹤0.01% of the portfolio, ranked #1675.

Sterling Capital Management first reported a position in RXRX in Q3 2024 and has held it in 8 quarters since. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Sterling Capital Management held 9,533 shares of Recursion Pharmaceuticals worth $35K as of Q2 2026.
  • Sterling Capital Management bought 6,557 Recursion Pharmaceuticals shares in Q2 2026, an estimated $21.8K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #1675 holding.
  • Sterling Capital Management first reported a position in Recursion Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.